Kabra Drugs Ltd (KABRADG)

Loading page…

Kabra Drugs Ltd (KABRADG) · mywealthgrid

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Standalone figures · ₹ crore · years without a filed annual are summed from quarters

₹ Cr	Mar 2016	Mar 2017	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	10	8	—	—	0	0	0	0	0	93
COGS	—	—	-1	—	0	0	0	0	0	84
Gross profit	—	—	—	—	—	—	—	—	—	9
	10	7	—	—	0	0	0	1	2	4
	0	0	—	—	-0	-0	-0	-1	-2	5
OPM %	0.6%	3.5%	—	—	—	—	—	—	—	5.8%
Depreciation	—	0	0	—	0	0	0	0	0	0
Interest	—	—	—	—	0	0	0	0	0	0
	—	—	—	—	0	0	0	0	1	0
Profit before tax	0	0	-2	-0	-0	-0	-0	-1	-1	6
Tax	—	—	—	—	0	0	0	0	0	1
Tax %	—	—	—	—	0%	0%	0%	0%	0%	13.3%
	0	0	-2	-0	-0	-0	-0	-1	-1	5
PAT margin %	0.8%	0%	—	—	—	—	—	—	—	5.4%
EPS (₹)	0.1	-0	-5.4	—	-0.4	0	-0.8	-1.7	-1	2.1
EPS adjusted (₹)	—	—	—	—	-0.4	-0.4	-0.8	-1.7	-0.5	2.1
Annual report	Annual report for Mar 2016	Annual report for Mar 2017	Annual report for Mar 2018	Annual report for Mar 2020	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	—

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	4	4	4	4	24	24
Reserves	—	-5	-5	-3	1	6
	—	1	1	2	0	0
	—	0	0	2	0	56
Total equity & liabilities	—	1	1	5	25	86
	0	0	0	0	0	1
CWIP	—	—	—	—	—	—
Investments	—	0	0	0	0	0
	—	1	1	5	25	86
Total assets	—	1	1	5	25	86

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-0	-0	-0	-0	-5	-9
	0	0	0	0	-0	-1
	0	0	0	3	23	0
Net cash flow	0	0	0	3	19	-11
Free cash flow	-0	—	—	—	-5	-10
CFO / Operating profit %	—	—	—	—	—	-177.7%

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Standalone figures

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	—	9.8%
EBITDA margin %	—	—	—	—	—	—	—	5.8%
EBIT margin %	—	—	—	—	—	—	—	5.7%
PAT margin %	—	—	—	—	—	—	—	5.4%
Working capital
Receivable days	—	—	—	—	—	—	—	279
Inventory days	—	—	—	—	—	—	—	0
Payable days	—	—	—	—	—	—	—	239
NWC days	—	—	—	—	—	—	—	39
Leverage
Current ratio	—	—	—	0.63	0.48	1.3	44.14	1.49
Debt to EBITDA	—	—	—	—	—	—	—	0.08
Debt to equity	—	—	—	-2.64	-1.89	1.58	0.02	0.01
Interest coverage	—	—	—	—	—	—	—	191.7
Asset turnover	—	—	—	0	0	0	0	1.07
Return ratios
Return on assets %	—	—	—	-26%	-48.6%	-16.2%	-4.3%	5.7%
Return on capital employed %	—	—	—	48.7%	45.2%	-68.5%	-8.5%	21.1%
Return on equity %	—	—	—	48.7%	46.6%	-68.5%	-4.4%	16.7%

Derived from reported annual statements. ROCE uses EBIT over capital employed (total assets less current liabilities). Day counts average the opening and closing balance; receivables turn on revenue, inventory and payables on cost of goods sold.

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoter	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
FII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
DII	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
No. of shareholders	—	—	—	—	—	—	—	—	8,098	8,862	9,185	9,680

Promoter holding up 0 percentage points since Sep 2023.

13 deals · 10 Jun 2024 – 2 Jan 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
2 Jan 2026	KRUTI SEVANTI DOSHI	Bulk	BSE	Sell	1,30,810	₹31.82	₹0.42 Cr
1 Jan 2026	KRUTI SEVANTI DOSHI	Bulk	BSE	Sell	1,43,190	₹31.20	₹0.45 Cr
24 Dec 2025	KRUTI SEVANTI DOSHI	Bulk	BSE	Sell	1,26,000	₹30.19	₹0.38 Cr
22 Dec 2025	MIRAL HEMANTBHAI BHOOT	Bulk	BSE	Sell	1,19,000	₹27.55	₹0.33 Cr
20 Nov 2025	SELVAMURTHY AKILANDESWARI	Bulk	BSE	Buy	1,91,422	₹26.89	₹0.51 Cr
20 Nov 2025	VIJAY KUMAR REDDY VEERAMREDDY	Bulk	BSE	Sell	1,50,519	₹27.63	₹0.42 Cr
20 Nov 2025	SOUMYA MALANI .	Bulk	BSE	Buy	1,50,000	₹27.65	₹0.41 Cr
18 Jul 2025	ISHAAN TRADEFIN LLP	Bulk	BSE	Sell	1,36,442	₹22.26	₹0.30 Cr
18 Jul 2025	ISHAAN TRADEFIN LLP	Bulk	BSE	Buy	7,717	₹21.87	₹0.02 Cr
16 Jul 2025	ISHAAN TRADEFIN LLP	Bulk	BSE	Buy	1,37,393	₹20.25	₹0.28 Cr

1–10 of 13

1 / 2

Bulk deals are a client trading over 0.5% of the equity in a session, aggregated across their trades; block deals are single negotiated trades in the exchange’s block window. Each is reported by the exchange it was crossed on, so NSE and BSE rows are separate trades rather than the same trade twice.

Mrs. ANAND ANITHANon-Executive - Independent Director-Chairperson
Mr. NANJAPPAN ARAVINDExecutive Director-MD
Mr. KUNIAMUTHUR NANJAPPAN ANANDExecutive Director
Ms. RITU TIWARINon-Executive - Independent Director
Ms. NIKITA SINHANon-Executive - Independent Director
Ms. MONAM KAPOORNon-Executive - Independent Director
Mr. T. PavanasamChief Financial Officer
Mr. Monika Nishant GattaniCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

Ratio	Mar 2018	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	—	—	—	—	—	—	—	9.8%
EBITDA margin %	—	—	—	—	—	—	—	5.8%
EBIT margin %	—	—	—	—	—	—	—	5.7%
PAT margin %	—	—	—	—	—	—	—	5.4%
Working capital
Receivable days	—	—	—	—	—	—	—	279
Inventory days	—	—	—	—	—	—	—	0
Payable days	—	—	—	—	—	—	—	239
NWC days	—	—	—	—	—	—	—	39
Leverage
Current ratio	—	—	—	0.63	0.48	1.3	44.14	1.49
Debt to EBITDA	—	—	—	—	—	—	—	0.08
Debt to equity	—	—	—	-2.64	-1.89	1.58	0.02	0.01
Interest coverage	—	—	—	—	—	—	—	191.7
Asset turnover	—	—	—	0	0	0	0	1.07
Return ratios
Return on assets %	—	—	—	-26%	-48.6%	-16.2%	-4.3%	5.7%
Return on capital employed %	—	—	—	48.7%	45.2%	-68.5%	-8.5%	21.1%
Return on equity %	—	—	—	48.7%	46.6%	-68.5%	-4.4%	16.7%

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Date	Category	Subject	Filing
1 Oct 2026, 4:12 pm	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Scrutinizer''s Report	PDF
30 Sept 2026, 9:37 am	AGM/EGM AGM	Shareholder Meeting / Postal Ballot-Outcome of AGM	PDF
28 Sept 2026, 4:25 pm	Insider Trading / SAST Closure of Trading Window	Closure of Trading Window	PDF
9 Sept 2026, 3:16 pm	Company Update Newspaper Publication	Announcement under Regulation 30 (LODR)-Newspaper Publication	PDF
8 Sept 2026, 7:16 pm	Others Reg. 34 (1) Annual Report	Reg. 34 (1) Annual Report.	PDF
7 Sept 2026, 6:43 pm	AGM/EGM AGM	Submission Of Notice Of Annual General Meeting Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulations, 2015	PDF
3 Sept 2026, 5:11 pm	Corp. Action Book Closure	Book Closure And Schedule Of Events For E-Voting.	PDF
2 Sept 2026, 6:48 pm	Company Update General	Appointment Of Internal Auditor Of The Company	PDF

Kabra Drugs Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

1

Announcements

Not in the F&O segment

1

No fund holdings on record

Announcements

Annual reports

Compounded sales growth

Return on equity

Kabra Drugs Ltd

About

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Cash flow

Ratios

Ratio timeline

Shareholding

Quarterly record

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

No fund holdings on record

Documents

Announcements

Events

Board meetings1

Announcements

Ratio timeline

Quarterly record

Bulk & block deals

Board and management

Not in the F&O segment

Board meetings1

No fund holdings on record

Announcements

Annual reports

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Return on equity

1

1